Home » Stocks » Ligand Pharmaceuticals

Ligand Pharmaceuticals Inc. (LGND)

Stock Price: $83.92 USD -1.10 (-1.29%)
Updated Oct 26, 2020 1:39 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 1.35B
Revenue (ttm) 126.39M
Net Income (ttm) -24.66M
Shares Out 16.08M
EPS (ttm) -1.44
PE Ratio n/a
Forward PE 13.40
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 26, 2020
Last Price $83.92
Previous Close $85.02
Change ($) -1.10
Change (%) -1.29%
Day's Open 84.49
Day's Range 82.87 - 85.55
Day's Volume 241,918
52-Week Range 57.24 - 127.80

More Stats

Market Cap 1.35B
Enterprise Value 998.25M
Earnings Date (est) Oct 30, 2020
Ex-Dividend Date n/a
Shares Outstanding 16.08M
Float 15.43M
EPS (basic) -0.27
EPS (diluted) -1.44
FCF / Share 1.57
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 1.87%
Payout Ratio n/a
Shares Short 9.84M
Short Ratio 32.27
Short % of Float 63.79%
Beta 1.44
PE Ratio n/a
Forward PE 13.40
P/FCF Ratio 53.51
PS Ratio 10.68
PB Ratio 1.96
Revenue 126.39M
Operating Income -4.45M
Net Income -24.66M
Free Cash Flow 25.22M
Net Cash 351.03M
Net Cash / Share 21.83
Gross Margin 41.95%
Operating Margin -3.52%
Profit Margin -19.50%
FCF Margin 19.95%
ROA -0.07%
ROE -2.84%
ROIC 0.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 6
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$181.67*
(116.48% upside)
Low
146
Current: $83.92
High
229
Target: 181.67
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue12025114110971.9164.5448.9731.3930.0423.54
Revenue Growth-52.17%78.21%29.48%51.53%11.43%31.78%56.02%4.5%27.61%-
Gross Profit10924513610366.1155.4043.2427.7925.1323.54
Operating Income80716468.0843.8927.3319.6314.940.19-2.58-31.01
Net Income62914312.56-1.6423012.0211.42-0.539.72-10.37
Shares Outstanding19.0021.1621.0320.8319.7920.4220.3119.8519.6619.61
Earnings Per Share31.855.960.53-0.0810.830.560.55-0.030.49-0.53
EPS Growth434.4%1024.53%--1833.93%1.82%----
Operating Cash Flow-29.3419488.5760.7341.7320.5720.690.16-1.17-27.07
Capital Expenditures-2.55-10.894.90-19.55-4.12-1.01-3.95-0.580.45-0.73
Free Cash Flow-31.8918393.4741.1937.6019.5616.74-0.41-0.72-27.80
Cash & Equivalents1,07079620614420516917.3215.1518.3824.04
Total Debt6496362252132021969.1128.2830.29-
Net Cash / Debt421160-18.99-68.663.02-27.318.21-13.13-11.9024.04
Assets1,4951,26167160250325810510412175.56
Liabilities72870025223122623455.1077.7810472.06
Book Value76756140034123726.3249.6126.498.19-4.85
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Ligand Pharmaceuticals Inc.
Country United States
Employees 115
CEO John L. Higgins

Stock Information

Ticker Symbol LGND
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: LGND
IPO Date November 18, 1992

Description

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; and Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations. It also offers bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Minnebro for the treatment of hypertension; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.